Nutritional safety and suitability of a specific protein hydrolysate derived from sources of skimmed cow's milk and whey protein concentrates and used in infant and follow-on formula manufactured from hydrolysed protein by Healthcare Reckitt B.V.

The European Commission (EC) requested the European Food Safety Authority to evaluate the nutritional safety and suitability of a specific protein hydrolysate derived from sources of skimmed cow's milk (including non-fat) and whey protein concentrates for use in infant and follow-on formula manufactured by Healthcare Reckitt B.V. Healthcare Reckitt B.

Scientific Opinion on additional scientific data related to the safety of monacolins from red yeast rice submitted pursuant to Article 8(4) of Regulation (EC) No 1925/2006.

The Panel on Nutrition, Novel Foods and Food Allergens (NDA) was asked to deliver a scientific opinion on the safety of monacolins from red yeast rice (RYR), which have been placed under Union scrutiny in Part C of Annex III in accordance with Article 8(4) of Regulation (EC) No 1925/2006. The NDA Panel reviewed the additional scientific data submitted during the period of scrutiny, which included analytical data on the composition of RYR supplements, the intake of monacolins from other dietary sources, in vitro bioaccessibility and cytotoxicity data of monacolins vs. other statins, nutrivigilance/post-marketing data, case reports and clinical studies.

Vitamin D status and muscle strength in a pan-European cohort of children and adolescents with normal weight and overweight/obesity.

Unlabelled: This aimed to investigate associations between the vitamin D status and handgrip strength in children and adolescents considering weight status. Participants aged 7 to < 16 years from the European IDEFICS/I.Family cohort were included.

Transition of clinical biomarker status from childhood into adolescence-A prospective study in children from eight European countries.

Purpose: Understanding factors influencing clinical biomarkers is important for the prevention of chronic disease. This study aimed to estimate transitions of biomarker status from childhood to adolescence and to identify determinants of biomarker status in early life in a prospective children cohort.

Subjects And Methods: Our sample comprised 1295 children participating in the baseline (2007/08) and second follow-up examination (2013/14) of the multi-center IDEFICS (Identification and prevention of Dietary- and lifestyle-induced health EFfects In Children and infantS)/I.

Safety of a change of specifications of phytosterols/phytostanols as a novel food pursuant to Regulation (EU) 2015/2283.

Following a request from the European Commission, the EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA) was asked to provide an opinion on the safety of a change of the specifications of the authorised NF 'phytosterols/phytostanols' as a novel food (NF) pursuant to Regulation (EU) 2015/2283. This authorised NF concerns phytosterols extracted from plants and which may be presented as free sterols and stanols or esterified with food grade fatty acids. It has to contain less than 81% β-sitosterol, less than 35% β-sitostanol, less than 40% campesterol, less than 15% campestanol, less than 30% stigmasterol and less than 3% brassicasterol.